Comprehensive Population Pharmacokinetics to Model the Time-varying Clearance of Sugemalimab, an Anti-Programmed Death-Ligand (PD-L1) Human Monoclonal Antibody, In Patients with Solid Tumors or Lymphomas Across Multiple Phase I-III Studies
作者:|发布:Chaohsuan Pan, Kun Wang, Fengyan Xu, et al.|发布时间: 2021-12-01|419 次浏览|分享到:
The 8th international symposium in quantitative pharmacology. December, 2021. [Poster]
